Chronic Lymphocytic Leukemia Clinical Trial
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory leukemia-cll/" >chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).
Eligibility Criteria
Inclusion Criteria:
Participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and high-risk features must have failed at least 2 lines of prior therapy and participants with CLL or SLL and standard risk features must have failed at least 3 lines of prior therapy
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure
Has recovery to Grade ≤ 1 or baseline of any non-hematologic toxicities due to previous therapy, except alopecia (any Grade acceptable) and peripheral neuropathy (Grade ≤ 2 acceptable)
Exclusion Criteria:
Any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, that places the subject at unacceptable risk if they were to participate in the study
Systemic fungal, bacterial, viral, or other infection that is not controlled
Active autoimmune disease requiring immunosuppressive therapy
Progressive deep vein thrombosis or pulmonary embolism requiring treatment, but not yet on a stable anticoagulation regimen
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 26 Locations for this study
Boston Massachusetts, 02114, United States More Info
Cincinnati Ohio, 45219, United States
Cincinnati Ohio, 45267, United States
Columbus Ohio, 43210, United States More Info
Houston Texas, 77030, United States
Milwaukee Wisconsin, 53226, United States
Calgary Alberta, T2N 4, Canada
Halifax Nova Scotia, B3H 2, Canada
Toronto Ontario, M5G 2, Canada
Cambridge , CB2 0, United Kingdom
Leeds , LS9 7, United Kingdom
London , NW12P, United Kingdom
Manchester , M20 4, United Kingdom
How clear is this clinincal trial information?